Innate Pharma (Innate Pharma) 3-Year Book Growth Rate : -31.20% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma 3-Year Book Growth Rate?

Innate Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $0.70.

During the past 12 months, Innate Pharma's average Book Value per Share Growth Rate was -5.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -31.20% per year. During the past 5 years, the average Book Value per Share Growth Rate was -28.20% per year. During the past 10 years, the average Book Value per Share Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Innate Pharma was 29.50% per year. The lowest was -37.30% per year. And the median was 0.80% per year.

Competitive Comparison of Innate Pharma's 3-Year Book Growth Rate

For the Biotechnology subindustry, Innate Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Innate Pharma's 3-Year Book Growth Rate falls into.

Innate Pharma 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Innate Pharma (NAS:IPHA) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Innate Pharma 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Innate Pharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.